# Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

> **NCT00396175** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 355 (—)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** MK0906, finasteride / Duration of Treatment : 48 Weeks
- **DRUG:** Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks

## Key facts

- **NCT ID:** NCT00396175
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** 2000-01
- **Final completion:** —
- **Target enrollment:** 355 (—)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396175, "Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00396175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*